Skip to main content

Apheresis Unit (Hematology)

Apherisis is a procedure that makes it possible to separate the various elements of the blood, in particular: 

  • the plasma (therapeutic plasmapherisis),
  • the red corpuscles (therapeutic erythropheresis),
  • the white corpuscles (therapeutic leucapheresis),
  • the hematopoietic stem cells (cytapheresis), essential for both analogous transplants (using cells taken from the patient) and allogenic transplants (using the cells of another donor). 

Apheresis is a technique of extraction by centrifugation in an extracorporeal blood circuit (CEC). The components not collected are reinjected into the donor. 

The Apheresis Unit at the Jules Bordet Institute receives, for the ULB-IRIS network as a whole, patients likely to benefit from the collection of stem cells. The Unit works in close cooperation with the various autotransplant centres for adults and with the Children's Hospital (HUDERF). 

We have been practicing apheresis in our service since 1970, with a nursing and technical staff trained especially for the purpose. Three doctors and four nurses are available and ensure the continuity of the medical care, in cooperation with the hematology service as a whole. The Unit has an emergency service that operates 24 hours a day. 

The extraction, handling and conservation of the hematopoietic stem cells is in accordance with good practices. Since 2009 we have been accredited under the inspection programme (JACIE, the "Joint Accreditation Committee of the ISCT and EBMT" ) which makes it possible to improve quality within the various teams involved in carrying out the hematopoietic transplants.  

The Apheresis Unit at the Jules Bordet Institute also gives our patients access to treatment using photopheresis. This treatment is indicated for Chronic Graft Versus Host Disease (CGVHD) that does not respond to the standard treatment and in certain cases of skin lymphomas. 

 

Research projects


 

Project 1

A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECP™ for patients with refractory chronic GVHD
  • Project Initiator : Philippe Lewalle
  • Collaboration(s) : Protocole de la société belge d’hématologie
  • Financing (or) support: Amis de l’Institut Bordet

Our team

Responsible Physician
Prof Philippe Lewalle - Hematologist

Doctor
Dr Adriano Salaroli

Head Nurse
Patrick Crombez

Nurse(s)
Corine Mal
Walter Bellemans
Denise Duthoit
Nicoletta Munteanu
Olivier Mugema

Qualitician
Aurélie Timmermans
Olivier Carabin

Secretariat
Vanessa Vanpevenage

13/01/2020

 Scientific publications

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Authors : Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
Year : 2020
Journal : Lancet Haematol
Volume : 7
Pages : e511-e522

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Authors : Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P
Year : 2020
Journal : Leukemia

Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models.

Authors : Belhechmi S, Bin R, Rotolo F, Michiels S
Year : 2020
Journal : BMC Bioinformatics
Volume : 21
Pages : 277

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.

Authors : Pistilli B, Paci A, Ferreira AR, Di Meglio A, Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delaloge S, Michiels S, André F, Vaz-Luis I
Year : 2020
Journal : J Clin Oncol
Pages : JCO1901758

Sex Differences in the Response to Different Tinnitus Treatment.

Authors : Van der Wal A, Luyten T, Cardon E, Jacquemin L, Vanderveken OM, Topsakal V, Van de Heyning P, De Hertogh W, Van Looveren N, Van Rompaey V, Michiels S, Gilles A
Year : 2020
Journal : Front Neurosci
Volume : 14
Pages : 422